• Histologically confirmed prostate cancer.

• PSA ≥ 0.1 after radical prostatectomy.

• Candidate for salvage radiation and ADT treatment, as determined by treating physician.

• Age \>18 at the time of consent.

• ECOG Performance Status ≤ 2.

• Demonstrate adequate organ function as defined in the table below. All screening labs to be obtained within 90 days of registration.

• System Laboratory Value

• Hematological:

• Platelet count (plt) = ≥ 100,000/µL

• Hemoglobin (Hgb) = ≥ 9 g/dL

• Renal:

• eGFR = ≥ 30 mL/min using MDRD Formula

• Hepatic and Other:

• Bilirubin2 = ≤1.5 x upper limit of normal (ULN) Aspartate aminotransferase (AST) = ≤ 2.5 x ULN Alanine aminotransferase (ALT) = ≤ 2.5 x ULN Serum Albumin = \> 3.0 g/dL Serum potassium = ≥ 3.5 mmol/L 2In subjects with Gilbert's syndrome, if total bilirubin is \>1.5 x ULN, measure direct and indirect bilirubin; if direct bilirubin is ≤ 1.5 x ULN, subject may be eligible.

• Ability to understand and comply with study procedures for the entire length of the study as determined by the site investigator or protocol designee.

• Ability to understand English or Spanish language as determined by the site investigator or protocol designee. Since the primary outcome is a questionnaire available in English and Spanish.

• Written informed consent and HIPAA authorization for release of personal health information prior to registration. NOTE: HIPAA authorization may be included in the informed consent or obtained separately. Participants must have the ability to understand and willingness to sign the written informed consent document.